Patents by Inventor Michael T. Flavin
Michael T. Flavin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100144688Abstract: The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases. Thus, the present invention also comprises pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit cancer and treat, prevent, or inhibit the foregoing diseases.Type: ApplicationFiled: December 9, 2009Publication date: June 10, 2010Applicant: ADVANCED LIFE SCIENCES, INC.Inventors: Ali Koohang, Aye Aye Mar, Erika Szotek, Ze-Qi Xu, David A. Eiznhamer, Michael T. Flavin
-
Publication number: 20090062243Abstract: The present invention comprises lupine-type triterpenoids that inhibit cell proliferations, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit cancer and treat, prevent, or inhibit the foregoing diseases.Type: ApplicationFiled: July 10, 2008Publication date: March 5, 2009Applicant: ADVANCED LIFE SCIENCES, INC.Inventors: Ali Koohang, Aye Aye Mar, Erika Szotek, Ze-Qi Xu, David A. Eiznhamer, Michael T. Flavin
-
Patent number: 7122526Abstract: The present invention relates to anti-tumor compounds, compositions and methods.Type: GrantFiled: June 30, 2003Date of Patent: October 17, 2006Assignee: Nanosphere, Inc.Inventors: Ze-Qi Xu, Yasheen Zhou, Michael T. Flavin
-
Publication number: 20040077554Abstract: The present invention relates to anti-tumor compounds, compositions and methods. In particular, the invention relates to indolocarbazole analogues of the following general formulas that inhibit topoisomerase I activity.Type: ApplicationFiled: June 30, 2003Publication date: April 22, 2004Applicant: Advanced Life Sciences, Inc.Inventors: Ze-Qi Xu, Yasheen Zhou, Michael T. Flavin
-
Patent number: 6670383Abstract: The present invention relates to compounds and compositions useful in treating or preventing conditions and diseases related to Mycobacterium infection, and methods of use directed thereto.Type: GrantFiled: March 15, 2002Date of Patent: December 30, 2003Assignee: Advanced Life Sciences, Inc.Inventors: Ze-Qi Xu, Krzysztof Pupek, Livia Enache, Michael T. Flavin
-
Publication number: 20030083369Abstract: The present invention relates to compounds and compositions useful in treating or preventing conditions and diseases related to Mycobacterium infection, and methods of use directed thereto.Type: ApplicationFiled: March 15, 2002Publication date: May 1, 2003Inventors: Ze-Qi Xu, Krzysztof Pupek, Livia Enache, Michael T. Flavin
-
Publication number: 20020068757Abstract: Substantially purified antiviral biflavanoids robustaflavone, hinokiflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a, and GB-2a are provided. Antiviral biflavanoid derivatives and salt forms thereof, e.g., robustaflavone tetrasulfate potassium salt, and methods for preparing the same are also disclosed. Pharmaceutical compositions which include the antiviral biflavanoids, derivatives or salts thereof are also provided alone or in combination with at least one antiviral agent such as 3TC. Also disclosed is an improved method for obtaining substantially pure robustaflavone from plant material. The biflavanoid compounds, derivatives or salts thereof of the invention may be used in a method for treating and/or preventing viral infections caused by viral agents such as influenza, e.g., influenza A and B; hepatitis, e.g., hepatitis B; human immunodeficiency virus, e.g.Type: ApplicationFiled: January 17, 2001Publication date: June 6, 2002Applicant: Advanced Life Sciences, Inc.Inventors: Yuh-Meei Lin, David E. Zembower, Michael T. Flavin, Ralph Schure, Geng-Xian Zhao
-
Patent number: 6399654Abstract: Substantially purified antiviral biflavanoids robustaflavone, hinokiflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a, and GB-2a are provided. Antiviral biflavanoid derivatives and salt forms thereof, e.g., robustaflavone tetrasulfate potassium salt, and methods for preparing the same are also disclosed. Pharmaceutical compositions which include the antiviral biflavanoids, derivatives or salts thereof are also provided alone or in combination with at least one antiviral agent such as 3TC. Also disclosed is an improved method for obtaining substantially pure robustaflavone from plant material. The biflavanoid compounds, derivatives or salts thereof of the invention may be used in a method for treating and/or preventing viral infections caused by viral agents such as influenza, e.g., influenza A and B; hepatitis, e.g., hepatitis B; human immunodeficiency virus, e.g.Type: GrantFiled: April 15, 1998Date of Patent: June 4, 2002Assignee: Advanced Life Sciences, Inc.Inventors: Yuh-Meei Lin, David E. Zembower, Michael T. Flavin, Ralph Schure, Geng-Xian Zhao
-
Publication number: 20020013478Abstract: Calanolide analogues that demonstrate potent antiviral activity against many viruses are provided. Also provided is a method of using calanolide analogues for treating or preventing viral infections. The calanolide analogues provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.Type: ApplicationFiled: March 21, 2001Publication date: January 31, 2002Applicant: Sarawak Medichem Pharmaceuticals,Inc.Inventors: Ze-Qi Xu, Michael T. Flavin, David Zembower
-
Publication number: 20010027209Abstract: Calanolides and analogues thereof that demonstrate potent mycobacterium activity are provided. Also provided is a method of using calanolides and analogues thereof for treating or preventing mycobacterium infections. The calanolides and analogues thereof provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.Type: ApplicationFiled: December 11, 2000Publication date: October 4, 2001Applicant: Sarawak Medichem Pharmaceuticals, Inc.Inventors: Ze-Qi Xu, Yuh Meei Lin, Michael T. Flavin
-
Publication number: 20010021902Abstract: A method and workstation for optimizing chemical processes based on combinatorial chemistry, automation technology, and computer-controlled design is disclosed. The workstation includes a synthesizer, an analyzer, a robot and computer in communication with the synthesizer and analyzer. The computer includes one or more programs for regulating reaction parameters such as temperature, pressure, concentration of reagents and employs statistical methods for optimizing multiple reaction parameters and for designing optimized experiments for further investigation.Type: ApplicationFiled: December 14, 2000Publication date: September 13, 2001Inventors: Michael T. Flavin, Lisa M. Seaney
-
Patent number: 6277879Abstract: Calanolide analogues that demonstrate potent antiviral activity against many viruses are provided. Also provided is a method of using calanolide analogues for treating or preventing viral infections. The calanolide analogues provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.Type: GrantFiled: October 15, 1998Date of Patent: August 21, 2001Assignee: Sarawak Medichem Pharmaceuticals, Inc.Inventors: Ze-Qi Xu, Michael T. Flavin, David Zembower
-
Patent number: 6268393Abstract: Calanolides and analogues thereof that demonstrate potent mycobacterium activity are provided. Also provided is a method of using calanolides and analogues thereof for treating or preventing mycobacterium infections. The calanolides and analogues thereof provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.Type: GrantFiled: October 14, 1999Date of Patent: July 31, 2001Assignee: Sarawak Medichem PharmaceuticalsInventors: Ze-Qi Xu, Yuh Meei Lin, Michael T. Flavin
-
Patent number: 6225481Abstract: Robustaflavone, intermediates and analogues thereof and a method for synthesizing the same are provided. The method involves constructing apigenin ethers containing functionalities at the 6- and 3′-positions which could be cross-coupled using transition metal catalysis. The method also involves development of a regioselective iodination of an apigenin derivative at the 6-position, formation of an apigenin 3′-boronate using a palladium-catalyzed exchange of the corresponding 3′-iodide with a diboron reagent. Finally, Suzuki coupling to form the sterically congested 6-3′″ biaryl bond of robustaflavone provides access to the desired biflavanoid system. Robustaflavone intermediates and analogues may be used to prepare analogues of other biflavanoids such as hinokifavone, rhusflavone and succedaneaflavone.Type: GrantFiled: August 21, 1998Date of Patent: May 1, 2001Assignee: Advanced Life Sciences, Inc.Inventors: David E. Zembower, Heping Zhang, Michael T. Flavin, Yuh-Meei Lin
-
Patent number: 6175816Abstract: A method and workstation for optimizing chemical processes based on combinatorial chemistry, automation technology, and computer-controlled design is disclosed. The workstation includes a synthesizer, an analyzer, a robot and computer in communication with the synthesizer and analyzer. The computer includes one or more programs for regulating reaction parameters such as temperature, pressure, concentration of reagents and employs statistical methods for optimizing multiple reaction parameters and for designing optimized experiments for further investigation.Type: GrantFiled: November 19, 1999Date of Patent: January 16, 2001Assignee: Advanced Life Sciences, Inc.Inventors: Michael T. Flavin, Lisa M. Seaney
-
Patent number: 6160131Abstract: An efficient and scalable method is reported for the isolation of costatolide (2), an HIV-1-specific nonnucleoside reverse transcriptase inhibitor (NNRTI), from the latex of Calophyllum plants such as C. teysmannii var. inophylloide. An overall yield of 10.6% of costatolide, with a purity of 96%, was obtained by repetitive recrystallization of the latex from a single organic solvent after the oily material was removed by treatment with hexane. A second major component of the latex, soulattrolide (3), another HIV-1 NNRTI, was also isolated. Both compounds were characterized by spectroscopic and chromatographic analyses and their in vitro anti-HIV activities were also confirmed. The results suggest that sufficient supplies of costatolide can be obtained in a relatively low-cost manner from natural sources.Type: GrantFiled: December 17, 1998Date of Patent: December 12, 2000Assignee: Sarawak Medichem Pharmaceuticals, Inc.Inventors: Yuh-Meei Lin, Herbert M. Anderson, Tuah R. Jenta, Michael J. Williams, Michael T. Flavin, Ze-Qi Xu
-
Patent number: 6043271Abstract: A method of preparing (.+-.)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (.+-.)-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (.+-.)-calanolide A. A method for resolving (.+-.)-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing a viral infections using (.+-.)-calanolide or (-)-calanolide is provided.Type: GrantFiled: August 2, 1995Date of Patent: March 28, 2000Assignee: Sarawak MediChem Pharmaceuticals, Inc.Inventors: Michael T. Flavin, Ze-Qi Xu, John D. Rizzo, Alla Kucherenko, Albert Khilevich, Abram Kivovich Sheinkman, Vilayphone Vilaychack, Lin Lin, Wei Chen, William A. Boulanger
-
Patent number: 6044212Abstract: A method and workstation for optimizing chemical processes based on combinatorial chemistry, automation technology, and computer-controlled design is disclosed. The workstation includes a synthesizer, an analyzer, a robot and computer in communication with the synthesizer and analyzer. The computer includes one or more programs for regulating reaction parameters such as temperature, pressure, concentration of reagents and employs statistical methods for optimizing multiple reaction parameters and for designing optimized experiments for further investigation.Type: GrantFiled: May 23, 1997Date of Patent: March 28, 2000Assignee: Advanced Life Sciences, Inc.Inventors: Michael T. Flavin, Lisa M. Seaney
-
Patent number: 5981770Abstract: A method of preparing (+)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. According to the disclosed method, chromene 4 intermediate was subjected to a chlorotitanium-mediated aldol reaction with acetaldehyde to selectively produce (.+-.)-8a. Separation and enzyme-mediated resolution of (.+-.)-8a produced (+)-8a. Cyclization of (+)-8a under neutral Mitsunobu conditions followed by Luche reduction of (+)-7 produced (+)-calanolide A in high yield and enantiomeric purity. The method of the invention has been extended to produce potent antiviral calanolide A analogues.Type: GrantFiled: September 5, 1997Date of Patent: November 9, 1999Assignee: Sarawak MediChem Pharmaceuticals, Inc.Inventors: Michael T. Flavin, Ze-Qi Xu, Albert Khilevich, David Zembower, John D. Rizzo, Shuyuan Liao, Aye Mar, Lin Lin, Vilayphone Vilaychack, Darko Brankovic, Sergey Dzekhster, Jinjun Liu
-
Patent number: 5977385Abstract: A method of preparing (+)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. According to the disclosed method, chromene 4 intermediate was subjected to a chlorotitanium-mediated aldol reaction with acetaldehyde to selectively produce (.+-.)-8a. Separation and enzyme-mediated resolution of (.+-.)-8a produced (+)-8a. Cyclization of (+)-8a under neutral Mitsunobu conditions followed by Luche reduction of (+)-7 produced (+)-calanolide A in high yield and enantiomeric purity. The method of the invention has been extended to produce potent antiviral calanolide A analogues.Type: GrantFiled: July 15, 1998Date of Patent: November 2, 1999Assignee: Sarawak MediChem PharmaceuticalsInventors: Michael T. Flavin, Ze-Qi Xu, Albert Khilevich, David Zembower, John D. Rizzo, Shuyuan Liao, Aye Mar, Lin Lin, Vilayphone Vilaychack, Darko Brankovic, Sergey Dzekhster, Jinjun Liu